• Molecular NameVinorelbine
  • SynonymVinorelbin; Vinorelbina [Spanish]; vinorelbine; Vinorelbine Bitartrate; Vinorelbine Ditartarate; Vinorelbine Ditartrate; Vinorelbine Tartrate; Vinorelbinum [Latin]
  • Weight778.947
  • Drugbank_IDDB00361
  • ACS_NO71486-22-1
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.3
  • pka5.4
  • LogD (pH=7, predicted)3.52
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.92
  • LogSw (predicted, AB/LogsW2.0)0.98
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors2
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds10
  • TPSA133.87
  • StatusFDA approved
  • AdministrationIntravenous, oral
  • PharmacologyAn anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability27.0
  • Protein binding87.0
  • Volume of distribution (VD)76 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP3A4-mediated)
  • Half life42 h
  • ExcretionFecal (46%) and renal (18%)
  • Urinary Excretion11
  • Clerance21 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A